Literature DB >> 7581005

Study of retinoic acid effect upon retinoic acid receptors beta (RAR-beta) in C6 cultured glioma cells.

P Reboul1, P George, P Louisot, P Broquet.   

Abstract

Using monoclonal antibodies against the RAR-alpha and RAR-beta retinoic receptors, we demonstrated that these receptors were present together in C6 glioma cells as two isoforms of 50 and 55 kDa. For RAR-beta, the 50 kDa isoform predominated (60 to 80% of the total of the two isoforms). After a treatment for 48 h with retinoic acid 10 microM, the 55 kDa form was enhanced, while no effect was observed either on RAR-alpha isoforms from C6 cells and on both RAR-alpha and RAR-beta forms from neuroblastoma SKN SH SY5Y used as a control. Using purified neuronal and glial rat brain nuclei, we showed that the 55 kDa isoform from RAR-beta predominated in glial cells. These results suggest that retinoic acid treatment of C6 cells led to a partial differentiation, the enhancement of the heavy form of RAR-beta being a marker of this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581005

Source DB:  PubMed          Journal:  Biochem Mol Biol Int        ISSN: 1039-9712


  4 in total

1.  Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.

Authors:  Caecilia Wismeth; Peter Hau; Klaus Fabel; Ulrike Baumgart; Birgit Hirschmann; Horst Koch; Tanja Jauch; Oliver Grauer; Lisa Drechsel; Alexander Brawanski; Ulrich Bogdahn; Andreas Steinbrecher
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

2.  Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Authors:  Jennifer L Clarke; Fabio M Iwamoto; Joohee Sul; Katherine Panageas; Andrew B Lassman; Lisa M DeAngelis; Adília Hormigo; Craig P Nolan; Igor Gavrilovic; Sasan Karimi; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

3.  Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma.

Authors:  M W Pitz; M Lipson; B Hosseini; P Lambert; K Guilbert; D Lister; G Schroeder; K Jones; C Mihalicioiu; D D Eisenstat
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

Review 4.  Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.

Authors:  Danijela Drakulic; Marija Schwirtlich; Isidora Petrovic; Marija Mojsin; Milena Milivojevic; Natasa Kovacevic-Grujicic; Milena Stevanovic
Journal:  Cells       Date:  2022-08-15       Impact factor: 7.666

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.